Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Harvard Business School
Moodys
McKinsey
Colorcon

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Staurosporine

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Staurosporine?

Staurosporine is an investigational drug.

There have been 29 clinical trials for Staurosporine. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2017.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are National Cancer Institute (NCI), University Health Network, Toronto, and Memorial Sloan Kettering Cancer Center.

There are two US patents protecting this investigational drug and twenty international patents.

Recent Clinical Trials for Staurosporine
TitleSponsorPhase
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeNational Cancer Institute (NCI)Phase 2/Phase 3
Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-TransplantNational Cancer Institute (NCI)Phase 2
Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-TransplantStanford UniversityPhase 2

See all Staurosporine clinical trials

Clinical Trial Summary for Staurosporine

Top disease conditions for Staurosporine
Top clinical trial sponsors for Staurosporine

See all Staurosporine clinical trials

US Patents for Staurosporine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Staurosporine   Start Trial Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC)   Start Trial
Staurosporine   Start Trial Pyrazol-3-ones that activate pro-apoptotic BAX Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
Staurosporine   Start Trial Tapered looped suture Covidien LP (Mansfield, MA)   Start Trial
Staurosporine   Start Trial Compositions and methods for inhibiting intimal hyperplasia   Start Trial
Staurosporine   Start Trial Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III Frequency Therapeutics, Inc. (Woburn, MA)   Start Trial
Staurosporine   Start Trial Benzimidazole derivatives as bromodomain inhibitors Gilead Sciences, Inc. (Foster City, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Staurosporine

Drugname Country Document Number Estimated Expiration Related US Patent
Staurosporine World Intellectual Property Organization (WIPO) 2015148714 2034-03-25   Start Trial
Staurosporine Australia 2012322660 2031-10-11   Start Trial
Staurosporine Australia 2017228527 2031-10-11   Start Trial
Staurosporine Canada 2851788 2031-10-11   Start Trial
Staurosporine European Patent Office 2766355 2031-10-11   Start Trial
Staurosporine World Intellectual Property Organization (WIPO) 2013055949 2031-10-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Medtronic
AstraZeneca
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.